Monday - May 5, 2025
PLANO, Texas, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that it plans to release financial and operational results for fourth quarter and full year 2024 at 7 a.m. Central Time (CT) / 8 a.m. Eastern Time (ET) on Thursday, February 20, 2025. Following the release, Integer management will host a webcast at 8 a.m. CT / 9 a.m. ET to discuss these results. Other forward-looking and material information may also be discussed during this call.
Conference call details:
An audio replay will be available for seven days and can be accessed by dialing (800) 770-2030 or (609) 800-9909 and using Conference ID 3120125. The conference call will also be available live or via archived replay on the Investor Relations section of the Integer website at: investor.integer.net.
From time to time, the Company posts information that may be of interest to investors on its website at investor.integer.net. To automatically receive Integer financial news by email, please visit investor.integer.net and subscribe to email alerts.
About Integer®
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company's brands include Greatbatch Medical® and Lake Region Medical. Additional information is available at www.integer.net.
Investor Relations: Andrew Senn andrew.senn@integer.net 763.951.8312 | Media Relations: Kelly Butler kelly.butler@integer.net 469.731.6617 |
Last Trade: | US$116.55 |
Daily Change: | -9.11 -7.25 |
Daily Volume: | 1,065,540 |
Market Cap: | US$3.910B |
April 24, 2025 April 24, 2025 March 18, 2025 March 12, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load